Hillsdale Investment Management Inc. Cyma Bay Therapeutics, Inc. Transaction History

Hillsdale Investment Management Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$12.63 - $24.47 $378 - $734	-30 Reduced 8.82%	310 $7,000
Q3 2023 Nov 09, 2023	BUY	$10.86 - $17.62 $3,692 - $5,990	340 New	340 $5,000
Q1 2021 Apr 22, 2021	SELL	$4.23 - $6.55 $521,559 - $807,615	-123,300 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$5.73 - $9.03 $229,200 - $361,200	-40,000 Reduced 24.49%	123,300 $708,000
Q3 2020 Nov 13, 2020	SELL	$3.32 - $7.24 $175,960 - $383,720	-53,000 Reduced 24.5%	163,300 $1.18 Million
Q2 2020 Aug 11, 2020	BUY	$1.41 - $4.25 $304,983 - $919,275	216,300 New	216,300 $755,000
Q2 2018 Aug 13, 2018	SELL	$10.66 - $14.38 $85,280 - $115,040	-8,000 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$9.0 - $15.16 $72,000 - $121,280	8,000 New	8,000 $104,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.